New Drugs Approved

New drugs approved since October 2005

Product name Indication New drugs approved Launched
Psychiatry & Neurology Area
KYNMOBI® (apomorphine HCl) * OFF episodes associated with Parkinson's disease May 2020 Sep. 2020
APTIOM® (eslicarbazepine acetate) * Epilepsy Nov. 2013 Apr. 2014
LATUDA® (lurasidone hydrochloride) * Schizophrenia, Bipolar l depression Oct. 2010 Feb. 2011
TRERIEF® (zonisamide) Parkinson’s disease Jan. 2009 Mar. 2009
LONASEN® (blonanserin) Schizophrenia Jan. 2008 Apr. 2008
Cardiovascular/ Diabetes Area
TWYMEEG® (imeglimin) Type 2 diabetes Jun. 2021 Sep. 2021
AIMIX® (amlodipine besilate / irbesartan) Hypertension / Combination tablets Sep. 2012 Dec. 2012
SUREPOST® (repaglinide) The reduction of postprandial blood glucose in patients with type 2 diabetes Jan. 2011 May 2011
METGLUCO® (metformin hydrochloride) Type 2 diabetes Jan. 2010 Apr. 2010
AVAPRO® (irbesartan) Hypertension Apr. 2008 Jun. 2008
Cancer and Infectious Diseases Area
ORGOVYX® (relugolix) * Prostate cancer Dec. 2020 Jan. 2021
RETHIO® (thiotepa) Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) for pediatric solid tumors Mar. 2019 May 2019
MIRIPLA® (miriplatin hydrate) Lipiodolization in hepatocellular carcinoma Oct. 2009 Dec. 2009
AmBisome® (amphotericin B) Systemic fungal infection, febrile neutropenia suspected to be caused by fungal infection, visceral leishmaniasis Apr. 2006 Jun. 2006
Regenerative medicine / Cell therapy
RETHYMIC® (allogeneic processed thymus tissue-agdc) * Pediatric congenital athymia Oct. 2021 Mar. 2022
Other Areas
MYFEMBREE® (relugolix combination tablet) * Uterine fibroids May 2021 Jun. 2021
GEMTESA® (vibegron) * Overactive bladder (OAB) Dec. 2020 Apr. 2021
LONHALA® MAGNAIR® (glycopyrronium bromide) * Chronic obstructive pulmonary disease (COPD) Dec. 2017 Apr. 2018

* Approved in the U.S.